Datopotamab deruxtecan

• UNSPSC Description:

  Datopotamab deruxtecan (DS-1062; Dato-DXd) is a trophoblast cell surface antigen 2 (TROP2)-directed antibody-drug conjugate (ADC). Datopotamab deruxtecan has a potent antitumor activity[1].

• Target Antigen:

  Antibody-Drug Conjugates (ADCs); Topoisomerase; TROP2

• Type:

  ADC Related

• Related Pathways:

  Antibody-drug Conjugate/ADC Related;Cell Cycle/DNA Damage;Immunology/Inflammation

• Applications:

  Cancer-programmed cell death

• Field of Research:

  Cancer

• Assay Protocol:

  https://www.medchemexpress.com/datopotamab-deruxtecan.html

• Solubility:

  10 mM in DMSO

• Smiles:

  [Datopotamab deruxtecan]

• Molecular Weight:

  149000 (average)

• References & Citations:

  [1]Daisuke Okajima, et al. Datopotamab Deruxtecan, a Novel TROP2-directed Antibody-drug Conjugate, Demonstrates Potent Antitumor Activity by Efficient Drug Delivery to Tumor Cells. Mol Cancer Ther. 2021 Aug 19.

• Shipping Conditions:

  Dry Ice

• Clinical Information:

  Phase 3

• CAS Number:

  2238831-60-0